167 related articles for article (PubMed ID: 28120114)
1. Longitudinal patterns of bone-targeted agent use among patients with solid tumors and bone metastases in the United States.
Qian Y; Bhowmik D; Kachru N; Hernandez RK
Support Care Cancer; 2017 Jun; 25(6):1845-1851. PubMed ID: 28120114
[TBL] [Abstract][Full Text] [Related]
2. Utilization of agents to prevent skeletal-related events among patients with multiple myeloma: analysis of real-world data.
Qian Y; Bhowmik D; Kachru N; Hernandez RK; Cheng P; Liede A
Support Care Cancer; 2018 Mar; 26(3):807-812. PubMed ID: 29063388
[TBL] [Abstract][Full Text] [Related]
3. Treatment Patterns of Bone-targeting Agents Among Solid Tumor Patients With Bone Metastases: An Analysis of Electronic Health Record Data in the United States From 2014 to 2018.
Nicholson G; Carlson KB; Hernandez RK; Schenfeld J; Cadieux B; Henry D; De Sousa Barbosa VJ; Saad H
Am J Clin Oncol; 2024 Apr; 47(4):177-184. PubMed ID: 38200688
[TBL] [Abstract][Full Text] [Related]
4. Patients with bone metastases from solid tumors initiating treatment with a bone-targeted agent in 2011: a descriptive analysis using oncology clinic data in the US.
Hernandez RK; Quigley J; Pirolli M; Quach D; Chen KS; Arellano J; Liede A
Support Care Cancer; 2014 Oct; 22(10):2697-705. PubMed ID: 24789499
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
6. Treatment dynamics of bone-targeting agents among men with bone metastases from prostate cancer in the United States.
Butler AM; Cetin K; Hernandez RK; Diane Reams B; Overman RA; I Kim J; Hirsch BR; Abernethy AP; Liede A; Alan Brookhart M
Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):229-238. PubMed ID: 29316026
[TBL] [Abstract][Full Text] [Related]
7. Real-world use of denosumab and bisphosphonates in patients with solid tumours and bone metastases in Germany.
Diel I; Ansorge S; Hohmann D; Giannopoulou C; Niepel D; Intorcia M
Support Care Cancer; 2020 Nov; 28(11):5223-5233. PubMed ID: 32086567
[TBL] [Abstract][Full Text] [Related]
8. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study.
Scagliotti GV; Hirsh V; Siena S; Henry DH; Woll PJ; Manegold C; Solal-Celigny P; Rodriguez G; Krzakowski M; Mehta ND; Lipton L; García-Sáenz JA; Pereira JR; Prabhash K; Ciuleanu TE; Kanarev V; Wang H; Balakumaran A; Jacobs I
J Thorac Oncol; 2012 Dec; 7(12):1823-1829. PubMed ID: 23154554
[TBL] [Abstract][Full Text] [Related]
9. A comprehensive review of denosumab for bone metastasis in patients with solid tumors.
Gül G; Sendur MA; Aksoy S; Sever AR; Altundag K
Curr Med Res Opin; 2016; 32(1):133-45. PubMed ID: 26451465
[TBL] [Abstract][Full Text] [Related]
10. Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours.
Zheng GZ; Chang B; Lin FX; Xie D; Hu QX; Yu GY; Du SX; Li XD
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27430483
[TBL] [Abstract][Full Text] [Related]
11. Bone-targeted agent treatment patterns and the impact of bone metastases on patients with advanced breast cancer in the United States.
Henry D; von Moos R; Body JJ; Rider A; De Courcy J; Bhowmik D; Gatta F; Hechmati G; Qian Y
Curr Med Res Opin; 2019 Mar; 35(3):375-381. PubMed ID: 30550358
[TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
[TBL] [Abstract][Full Text] [Related]
13. Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study.
Diel IJ; Greil R; Janssen J; Kluike CW; Behera B; Abbasi A; Seesaghur A; Kellner M; Jaeger C; Bjorklof K; Tomova A; Haslbauer F
Support Care Cancer; 2022 Nov; 30(11):9267-9278. PubMed ID: 36066628
[TBL] [Abstract][Full Text] [Related]
14. Bone-targeting agents in major solid tumour metastases: a multinational cohort study.
Kim JH; Shen CY; Au PC; Baek YH; Cheung CL; Chung WP; Kleinman NJ; Lam TC; Liao TC; Lin TC; Shin JY; Sing CW; Wong ICK; Lai EC
BMJ Support Palliat Care; 2024 Jan; 13(e3):e1064-e1073. PubMed ID: 35177433
[TBL] [Abstract][Full Text] [Related]
15. Impact of denosumab use on the survival of untreated non-squamous non-small cell lung cancer patients with bone metastases.
Udagawa H; Niho S; Kirita K; Umemura S; Matsumoto S; Yoh K; Goto K
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1075-1082. PubMed ID: 28220258
[TBL] [Abstract][Full Text] [Related]
16. Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics.
Lipton A; Fizazi K; Stopeck AT; Henry DH; Smith MR; Shore N; Martin M; Vadhan-Raj S; Brown JE; Richardson GE; Saad F; Yardley DA; Zhou K; Balakumaran A; Braun A
Eur J Cancer; 2016 Jan; 53():75-83. PubMed ID: 26693901
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases: a systematic review and meta-analysis.
Sun L; Yu S
Am J Clin Oncol; 2013 Aug; 36(4):399-403. PubMed ID: 22772430
[TBL] [Abstract][Full Text] [Related]
18. Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States.
Hernandez RK; Wade SW; Reich A; Pirolli M; Liede A; Lyman GH
BMC Cancer; 2018 Jan; 18(1):44. PubMed ID: 29306325
[TBL] [Abstract][Full Text] [Related]
19. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid.
Cleeland CS; Body JJ; Stopeck A; von Moos R; Fallowfield L; Mathias SD; Patrick DL; Clemons M; Tonkin K; Masuda N; Lipton A; de Boer R; Salvagni S; Oliveira CT; Qian Y; Jiang Q; Dansey R; Braun A; Chung K
Cancer; 2013 Feb; 119(4):832-8. PubMed ID: 22951813
[TBL] [Abstract][Full Text] [Related]
20. Prospective observational study to evaluate the persistence of treatment with denosumab in patients with bone metastases from solid tumors in routine clinical practice: final analysis.
Haslbauer F; Petzer A; Safanda M; Tomova A; Porubska M; Bajory Z; Niepel D; Jaeger C; Bjorklof K; Kalinin D; Greil R
Support Care Cancer; 2020 Apr; 28(4):1855-1865. PubMed ID: 31350601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
